Aslan Pharmaceuticals announces new data on eblasakimab, appointments

ASLAN Pharmaceuticals announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease, COPD, that provides further support for the potential of eblasakimab as a biologic therapy for COPD. In addition, the Company announced the appointment of respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, Associate Professor in Emergency Medicine, Harvard Medical School, and Dr Reynold Panettieri Jr, MD, Vice Chancellor, Translational Medicine and Science, Rutgers University to ASLAN’s Scientific Advisory Board as it evaluates the potential use of eblasakimab as a therapy to treat COPD in addition to atopic dermatitis, AD. “We believe that eblasakimab has the potential to be a leading treatment option as we explore its applicability in other diseases besides AD, such as COPD, a large, underserved market with no approved biologics. We look forward to working with Drs Krishnan and Panettieri, and potential partners, to consider potential proof-of-concept Phase 2 study designs in COPD and exploring novel endpoints from recently conducted biologic studies,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.